Quarterly ResultAug 6, 2026, 04:14 PM
Lexicon Secures $100M Loan, Raises $96.2M Equity; Q2 Net Loss $(31.8)M
AI Summary
Lexicon Pharmaceuticals reported a net loss of $(31.8) million for Q2 2026, a significant decrease from a net income of $3.3 million in Q2 2025, primarily due to lower licensing revenue. Despite the operational loss, the company strengthened its financial position by securing a new $100 million Hercules Term Loan, with $55 million funded, and fully repaying its previous Oxford Term Loans. Additionally, Lexicon completed an equity offering and private placement in February 2026, raising approximately $96.2 million in net proceeds to support its pipeline and operations.
Key Highlights
- Secured new $100M Hercules Term Loan, with $55M funded at closing in May 2026.
- Repaid remaining $54.3M Oxford Term Loans, incurring a $4.3M loss on early extinguishment.
- Raised $40.6M net from common stock public offering in February 2026.
- Raised $55.6M gross from concurrent private placement of common and preferred stock.
- Reported Q2 2026 net loss of $(31.8)M, compared to net income of $3.3M in Q2 2025.
- Total revenues for Q2 2026 were $0.7M, down from $28.9M in Q2 2025.
- Cash and cash equivalents increased to $40.9M as of June 30, 2026.
- Received $20M in LX9851 development milestones from Novo Nordisk in Q1 2026.
Price Impact
More from LXRX